Vivimed Labs, a niche specialty chemicals and pharmaceuticals company, announced that it received approval for 2 products from Uzbekistan Government for its PICS & Health Canada approved site, both facilities are situated at Hyderabad.

Bilastin tablets is a second-generation antihistamine (a selective histamine Hi receptor antagonist) and it is used in the treatment of allergic Rhino conjunctivitis and Urticaria (hives).

Another product Orzole combi (Ofloxacin + Ornidazole) is used in the treatment of bacterial and parasitic infections. It is used to treat gastrointestinal infections such as acute diarrhoea or dysentery, gynaecological infections, lung infections and urinary infections.

Commenting on the approval, Ramesh Krishnamurthy, CEO of Vivimed Labs, said, "We are very excited to receive approval to Vivimed's own products. Vivimed strategy is to increase its share of Branded products in CIS Markets. Vivimed shall be launching these products in 2021. Our purpose is to offer innovative & top quality formulations at affordable prices. This approval is testimony to Vivimed's growth strategy".